Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.

Breast cancer research and treatment - 1 Dec 2005

Mohsin Syed K, Allred D Craig, Osborne C Kent, Cruz Anatolio, Otto Pamela, Chew Helen, Clark Gary M, Elledge Richard M

Abstract excerpt

Prevention trials using incidence or mortality as endpoints require a large number of participants and long follow-up. Trials using biomarkers as endpoints would potentially require fewer participants, less time, and significantly less resources to test promising new agents for breast cancer prevention. To test this idea, a randomized trial of tamoxifen for 1 year versus observation for 1 year was conducted to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Biopsy, Needle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Chemoprevention

Share to Endpoint Determination

Share to Hyperplasia

Share to Mammography

Share to Tamoxifen

Source

Identifiers

PMID: 16267611
DOI: 10.1007/s10549-005-4896-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.PMID 16267611Read ↗

Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.Semantic proximity Read ↗

Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.Semantic proximity Read ↗

Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.Semantic proximity Read ↗

Benign breast disease and breast cancer risk: morphology and beyond.Semantic proximity Read ↗

Understanding the Molecular Basis of Histologic GradeSemantic proximity Read ↗

Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention.Semantic proximity Read ↗

Prevention of breast cancer.Semantic proximity Read ↗

Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials.Semantic proximity Read ↗

The preneoplastic phenotype in murine mammary tumorigenesis.Semantic proximity Read ↗

Tissue microarrays for comparing molecular features with proliferation activity in breast cancerSemantic proximity Read ↗

Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27.Semantic proximity Read ↗

Phenotypic alterations in breast cancer associated with neoadjuvant chemotherapy: A comparison with baseline rates of change.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.